Roberta Demichelis-Gómez1, Daniela Pérez-Sámano2, Christianne Bourlon2. 1. Department of Hematology and Oncology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Avenida Vasco de Quiroga No. 15, Belisario Dominguez Sección XVI, Tlalpan, 14080, Mexico City, Mexico. robertademichelis@gmail.com. 2. Department of Hematology and Oncology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Avenida Vasco de Quiroga No. 15, Belisario Dominguez Sección XVI, Tlalpan, 14080, Mexico City, Mexico.
Abstract
PURPOSE OF REVIEW: The purpose of this review is to discuss the current recommendations for the use of bispecific antibodies (bsAb) in hematologic malignancies and explore the future in this field. RECENT FINDINGS: Bispecific antibodies are molecules able to target two different antigen-binding sites: one towards a tumor antigen and another to activate a cytotoxic cell. Phase II/III trials on blinatumomab for acute lymphoblastic leukemia (ALL) have demonstrated its efficacy for treating minimal residual disease (MRD+) and relapsed refractory (r/r) Philadelphia positive (Ph+) and negative (Ph-) ALL in adults and children. Currently, the only bispecific antibody (bsAb) approved for its use in hematologic malignancies is blinatumomab. However, multiple trials are under development not only to explore blinatumomab's clinical activity in other neoplasia, such as lymphoma or multiple myeloma, but also to develop new molecules against different antigens.
PURPOSE OF REVIEW: The purpose of this review is to discuss the current recommendations for the use of bispecific antibodies (bsAb) in hematologic malignancies and explore the future in this field. RECENT FINDINGS: Bispecific antibodies are molecules able to target two different antigen-binding sites: one towards a tumor antigen and another to activate a cytotoxic cell. Phase II/III trials on blinatumomab for acute lymphoblastic leukemia (ALL) have demonstrated its efficacy for treating minimal residual disease (MRD+) and relapsed refractory (r/r) Philadelphia positive (Ph+) and negative (Ph-) ALL in adults and children. Currently, the only bispecific antibody (bsAb) approved for its use in hematologic malignancies is blinatumomab. However, multiple trials are under development not only to explore blinatumomab's clinical activity in other neoplasia, such as lymphoma or multiple myeloma, but also to develop new molecules against different antigens.
Authors: Hagop Kantarjian; Anthony Stein; Nicola Gökbuget; Adele K Fielding; Andre C Schuh; Josep-Maria Ribera; Andrew Wei; Hervé Dombret; Robin Foà; Renato Bassan; Önder Arslan; Miguel A Sanz; Julie Bergeron; Fatih Demirkan; Ewa Lech-Maranda; Alessandro Rambaldi; Xavier Thomas; Heinz-August Horst; Monika Brüggemann; Wolfram Klapper; Brent L Wood; Alex Fleishman; Dirk Nagorsen; Christopher Holland; Zachary Zimmerman; Max S Topp Journal: N Engl J Med Date: 2017-03-02 Impact factor: 91.245
Authors: Andreas Viardot; Marie-Elisabeth Goebeler; Georg Hess; Svenja Neumann; Michael Pfreundschuh; Nicole Adrian; Florian Zettl; Martin Libicher; Cyrus Sayehli; Julia Stieglmaier; Alicia Zhang; Dirk Nagorsen; Ralf C Bargou Journal: Blood Date: 2016-01-11 Impact factor: 22.113
Authors: George S Laszlo; Chelsea J Gudgeon; Kimberly H Harrington; Justine Dell'Aringa; Kathryn J Newhall; Gary D Means; Angus M Sinclair; Roman Kischel; Stanley R Frankel; Roland B Walter Journal: Blood Date: 2013-12-05 Impact factor: 22.113
Authors: S Hipp; Y-T Tai; D Blanset; P Deegen; J Wahl; O Thomas; B Rattel; P J Adam; K C Anderson; M Friedrich Journal: Leukemia Date: 2016-12-27 Impact factor: 11.528
Authors: Maria-Elisabeth Goebeler; Stefan Knop; Andreas Viardot; Peter Kufer; Max S Topp; Hermann Einsele; Richard Noppeney; Georg Hess; Stefan Kallert; Andreas Mackensen; Kathrin Rupertus; Lothar Kanz; Martin Libicher; Dirk Nagorsen; Gerhard Zugmaier; Matthias Klinger; Andreas Wolf; Brigitte Dorsch; Beate D Quednau; Margit Schmidt; Jürgen Scheele; Patrick A Baeuerle; Eugen Leo; Ralf C Bargou Journal: J Clin Oncol Date: 2016-02-16 Impact factor: 44.544
Authors: Christina Krupka; Peter Kufer; Roman Kischel; Gerhard Zugmaier; Jan Bögeholz; Thomas Köhnke; Felix S Lichtenegger; Stephanie Schneider; Klaus H Metzeler; Michael Fiegl; Karsten Spiekermann; Patrick A Baeuerle; Wolfgang Hiddemann; Gert Riethmüller; Marion Subklewe Journal: Blood Date: 2013-12-03 Impact factor: 22.113
Authors: Jean-Hugues Dalle; Adriana Balduzzi; Peter Bader; Anna Pieczonka; Isaac Yaniv; Arjan Lankester; Marc Bierings; Akif Yesilipek; Petr Sedlacek; Marianne Ifversen; Peter Svec; Jacek Toporski; Taifun Gungor; Jacek Wachowiak; Evgenia Glogova; Ulrike Poetschger; Christina Peters Journal: Bone Marrow Transplant Date: 2020-08-04 Impact factor: 5.483